External beam radiotherapy as curative treatment of prostate cancer

Mayo Clinic Proceedings

Volumn 80, Issue 7, 2005, Pages 883-898

  Pisansky, Thomas M ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIDIARRHEAL AGENT; BICALUTAMIDE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYPROTERONE; DIETHYLSTILBESTROL; ESTRAMUSTINE; FLUTAMIDE; GOSERELIN; MEGESTROL; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT CHEMOTHERAPY; ANORECTAL DISEASE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CYSTITIS; DIAGNOSTIC IMAGING; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DOSIMETRY; ENTERITIS; ERECTILE DYSFUNCTION; HEMATOCHEZIA; HUMAN; LASER; POSTOPERATIVE CARE; PROGNOSIS; PROSTATE CARCINOMA; PROSTATECTOMY; QUALITY OF LIFE; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; REVIEW; SEXUAL DYSFUNCTION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; URINARY TRACT OBSTRUCTION; URINE RETENTION;

EID: 21344432772     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/80.7.883     Document Type: Review

References (111)

1. Gilliland FD, Hoffman RM, Hamilton A, et al. Predicting extracapsular extension of prostate cancer in men treated with radical prostatectomy: results from the population based prostate cancer outcomes study [published correction appears in J Urol. 2000;163:1526]. J Urol. 1999;162:1341-1345.
2. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001;58:843-848.
3. Pisansky TM, Blute ML, Hillman DW, et al. The relevance of prostatectomy findings for brachytherapy selection in patients with localized prostate carcinoma. Cancer. 2002;95:513-519.
4. Pisansky TM, Blute ML, Suman VJ, Bostwick DG, Earle JD, Zincke H. Correlation of pretherapy prostate cancer characteristics with seminal vesicle invasion in radical prostatectomy specimens. Int J Radiat Oncol Biol Phys. 1996;36:585-591.
5. Pisansky TM, Zincke H, Suman VJ, Bostwick DG, Earle JD, Oesterling JE. Correlation of pretherapy prostate cancer characteristics with histologic findings from pelvic lymphadenectomy specimens. Int J Radiat Oncol Biol Phys. 1996;34:33-39.
6. Davis BJ, Pisansky TM, Wilson TM, et al. The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy. Cancer. 1999;85:2630-2637.
7. Roach M III, Pickett B, Rosenthal SA, Verhey L, Phillips TL. Defining treatment margins for six field conformal irradiation of localized prostate cancer. Int J Radiat Oncol Biol Phys. 1994;28:267-275.
8. Roach M III, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003;21:1904-1911.
9. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer [published correction appears in N Engl J Med. 2003;349:1010]. N Engl J Med. 2003;348:2491-2499.
10. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002.
11. Zagars GK, Pollack A, von Eschenbach AC. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era. Cancer. 1997;79:1370-1380.
12. Kattan MW, Zelefsky MJ, Kupelian PA, et al. Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. J Clin Oncol. 2003; 21:4568-4571.
13. Pisansky TM, Kahn MJ, Rasp GM, Cha SS, Haddock MG, Bostwick DG. A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostatic carcinoma. Cancer. 1997;79:337-344.
14. Kattan MW, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z, Leibel SA. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol. 2000;18:3352-3359.
15. Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer [published correction appears in J Urol. 2001;166:1839]. J Urol. 2001;166:876-881.
16. Kupelian PA, Elshaikh M, Reddy CA, Zippe C, Klein EA. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol. 2002;20:3376-3385.
17. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Andersen phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097-1105.
18. Kuban DA, Thames HD, Levy LB, et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2003;57:915-928.
19. Hanks GE, Hanlon AL, Pinover WH, Horwitz EM, Schultheiss TE. Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy. Cancer J Sci Am. 1999;5:152-158.
20. Roach M III, Lu J, Pilepich MV, et al. Long-term survival after radiotherapy alone: Radiation Therapy Oncology Group prostate cancer trials. J Urol. 1999;161:864-868.
21. Shipley WU, Thames HD, Sandler HM, et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA. 1999;281:1598-1604.
22. Pisansky TM, Kahn MJ, Bostwick DG. An enhanced prognostic system for clinically localized carcinoma of the prostate [published correction appears in Cancer. 1997;80:350]. Cancer. 1997;79:2154-2161.
23. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Chen MH. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure. J Urol. 2003;169:1320-1324.
24. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37:1035-1041.
25. Thames H, Kuban D, Levy L, et al. A comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys. 2003;57:929-943.
26. Kattan MW, Potters L, Blasko JC, et al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachy therapy in prostate cancer. Urology. 2001;58:393-399.
27. Swanson GP, Riggs MW, Earle JD. Long-term follow-up of radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2004;59:406-411.
28. Herman MG, Pisansky TM, Kruse JJ, Prisciandaro JI, Davis BJ, King BF. Technical aspects of daily online positioning of the prostate for three-dimensional conformal radiotherapy using an electronic portal imaging device. Int J Radiat Oncol Biol Phys. 2003;57:1131-1140.
29. Hanks GE, Leibel SA, Krall JM, Kramer S. Patterns of care studies: dose-response observations for local control of adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1985;11:153-157.
30. Pollack A, Smith LG, von Eschenbach AC. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys. 2000;48:507-512.
31. Horwitz EM, Hanlon AL, Pinover WH, Anderson PR, Hanks GE. Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques. Cancer. 2001;92:1281-1287.
32. Symon Z, Griffith KA, McLaughlin PW, Sullivan M, Sandler HM. Dose escalation for localized prostate cancer: substantial benefit observed with 3D conformal therapy. Int J Radiat Oncol Biol Phys. 2003;57:384-390.
33. Barry MJ, Albertsen PC, Bagshaw MA, et al. Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management: a retrospective analysis. Cancer. 2001;91:2302-2314.
34. Pisansky TM. Long-term follow-up of radiotherapy for prostate cancer [letter]. Int J Radiat Oncol Biol Phys. 2004;60:1663-1664.
35. Krongrad A, Lai H, Lamm SH, Lai S. Mortality in prostate cancer. J Urol. 1996;156:1084-1091.
36. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol. 2003;21:2163-2172.
37. Valicenti R, Lu J, Pilepich M, Asbell S, Grignon D. Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials. J Clin Oncol. 2000;18:2740-2746.
38. Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer. 2004;100:538-543.
39. Pisansky TM, Thames HD, Levy LB, et al. Clinical outcomes and prognostic factors in 4839 patients treated with external radiotherapy for stage T1-T2 prostate cancer [abstract]. Int J Radiat Oncol Biol Phys. 2004;60(suppl 1):S167. Abstract 63
40. Roach M, Lu J, Pilepich MV, et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials [published correction appears in Int J Radiat Oncol Biol Phys. 2000;48:313]. Int J Radiat Oncol Biol Phys. 2000;47:609-615.
41. Lawton CA, Winter K, Murray K, et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;49:937-946.
42. Pilepich MV, Winter K, John MJ, et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50:1243-1252.
43. Dearnaley DP, Khoo VS, Norman AR, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet. 1999;353:267-272.
44. Ryu JK, Winter K, Michalski JM, et al. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys. 2002;54:1036-1046.
45. Michalski JM, Winter K, Purdy JA, et al. Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II. Int J Radiat Oncol Biol Phys. 2003;56:192-198.
46. Lawton CA, Won M, Pilepich MV, et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys. 1991; 21:935-939.
47. Pilepich MV. Radiation Therapy Oncology Group studies in carcinoma of the prostate. NCI Monogr. 1988;7:61-65.
48. Lee WR, Schultheiss TE, Hanlon AL, Hanks GE. Urinary incontinence following external-beam radiotherapy for clinically localized prostate cancer. Urology. 1996;48:95-99.
49. Robinson JW, Dufour MS, Fung TS. Erectile functioning of men treated for prostate carcinoma. Cancer. 1997;79:538-544.
50. Zelefsky MJ, Eid JF. Elucidating the etiology of erectile dysfunction after definitive therapy for prostatic cancer. Int J Radiat Oncol Biol Phys. 1998; 40:129-133.
51. Roach M, Winter K, Michalski JM, et al. Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study. Int J Radiat Oncol Biol Phys. 2004;60:1351-1356.
52. Wernicke AG, Valicenti R, Dieva K, Houser C, Pequignot E. Radiation dose delivered to the proximal penis as a predictor of the risk of erectile dysfunction after three-dimensional conformal radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004;60:1357-1363.
53. Altwein J, Ekman P, Barry M, et al. How is quality of life in prostate cancer patients influenced by modern treatment? the Wallenberg Symposium. Urology. 1997;49(4A, suppl):66-76.
54. Fowler FJ Jr, Barry MJ, Lu-Yao G, Wasson JH, Bin L. Outcomes of external-beam radiation therapy for prostate cancer: a study of Medicare beneficiaries in three surveillance, epidemiology, and end results areas. J Clin Oncol. 1996;14:2258-2265.
55. Wei JT, Dunn RL, Sandler HM, et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol. 2002;20:557-566.
56. Clark JA, Inui TS, Silliman RA, et al. Patients' perceptions of quality of life after treatment for early prostate cancer. J Clin Oncol. 2003;21:3777-3784.
57. Little DJ, Kuban DA, Levy LB, Zagars GK, Pollack A. Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology. 2003;62:707-713.
58. Potosky AL, Davis WW, Hoffman RM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2004;96:1358-1367.
59. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the Expanded Prostate Cancer Index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56:899-905.
60. Talcott JA, Manola J, Clark JA, et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol. 2003;21:3979-3986.
61. Pilepich MV, Krall JM, Sause WT, et al. Prognostic factors in carcinoma of the prostate-analysis of RTOG study 75-06. Int J Radiat Oncol. Biol Phys. 1987;13:339-349.
62. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst. 2003;95:981-989.
63. Zagars GK, Pollack A, von Eschenbach AC. Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation. Cancer. 1997;80:764-775.
64. Zelefsky MJ, Lyass O, Fuks Z, et al. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy. J Clin Oncol. 1998;16:3380-3385.
65. Zagars GK, Pollack A, Smith LG. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1999; 44:809-819.
66. D'Amico AV, Schultz D, Loffredo M, et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA. 2000;284:1280-1283.
67. Pilepich MV, John MJ, Krall JM, McGowan D, Hwang YS, Perez CA. Phase II Radiation Therapy Oncology Group study of hormonal cytoreduction with flutamide and Zoladex in locally advanced carcinoma of the prostate treated with definitive radiotherapy. Am J Clin Oncol. 1990;13:461-464.
68. Pilepich MV, Buzydlowski JW, John MJ, Rubin P, McGowan DG, Marcial VA. Phase II trial of hormonal cytoreduction with megestrol and diethylstilbestrol in conjunction with radiotherapy for carcinoma of the prostate: outcome results of RTOG 83-07. Int J Radiat Oncol Biol Phys. 1995;32:175-180.
69. Zietman AL, Nakfoor BM, Prince EA, Gerweck LE. The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: an in vitro and in vivo study. Cancer J Sci Am. 1997;3:31-36.
70. Zietman AL, Prince EA, Nakfoor BM, Park JJ. Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. Int J Radiat Oncol Biol Phys. 1997;38:1067-1070.
71. Gleave ME, Goldenberg SL, Chin JL, et al, Canadian Uro-Oncology Group. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol. 2001;166:500-506.
72. Pilepich MV, Krall JM, John MJ, et al. Hormonal cytoreduction in locally advanced carcinoma of the prostate treated with definitive radiotherapy: preliminary results of RTOG 83-07. Int J Radiat Oncol Biol Phys. 1989;16:813-817.
73. Garnick MB, Fair WR, Bostwick D, et al. Overview consensus statement: Fifth International Conference on Neoadjuvant Hormonal Therapy for Prostate Cancer. Mol Urol. Fall 2000;4:89-92.
74. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360:103-106.
75. Zagars GK, Johnson DE, von Eschenbach AC, Hussey DH. Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study. Int J Radiat Oncol Biol Phys. 1988;14:1085-1091.
76. Schmidt JD, Gibbons RP, Murphy GP, Bartolucci A. Adjuvant therapy for localized prostate cancer. Cancer. 1993;71(3, suppl):1005-1013.
77. Schmidt JD, Gibbons RP, Murphy GP, Bartolucci A, Investigators of the National Prostate Cancer Project. Evaluation of adjuvant estramustine phosphate, cyclophosphamide, and observation only for node-positive patients following radical prostatectomy and definitive irradiation. Prostate. 1996;28:51-57.
78. Granfors T, Modig H, Damber JE, Tomic R. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol. 1998;159:2030-2034.
79. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02 [published correction appears in J Clin Oncol. 2004;22:386]. J Clin Oncol. 2003;21:3972-3978.
80. Sands ME, Pollack A, Zagars GK. Influence of radiotherapy on node-positive prostate cancer treated with androgen ablation. Int J Radiat Oncol Biol Phys. 1995;31:13-19.
81. Zagars GK, Sands ME, Pollack A, von Eschenbach AC. Early androgen ablation for stage D1 (N1 to N3, M0) prostate cancer: prognostic variables and outcome. J Urol. 1994;151:1330-1333.
82. Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol. 2003;170:1872-1876.
83. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol. 2000;164:101-105.
84. Lu-Yao GL, Potosky AL, Albertsen PC, Wasson JH, Barry MJ, Wennberg JE. Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J Natl Cancer Inst. 1996;88:166-173.
85. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999;17:1499-1507.
86. Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol. 2001;165:119-125.
87. Moul JW, Connelly RR, Lubeck DP, et al. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J Urol. 2001;166:1322-1327.
88. Anscher MS. Adjuvant radiotherapy following radical prostatectomy is more effective and less toxic than salvage radiotherapy for a rising prostate specific antigen. Int J Cancer. 2001;96:91-93.
89. Schild SE, Wong WW, Grado GL, et al. The result of radical retropubic prostatectomy and adjuvant therapy for pathologic stage C prostate cancer. Int J Radiat Oncol Biol Phys. 1996;34:535-541.
90. Valicenti RK, Gomella LG, Ismail M, et al. The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys. 1999;45:53-58.
91. Leibovich BC, Engen DE, Patterson DE, et al. Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin. J Urol. 2000;163:1178-1182.
92. Schild SE, Pisansky TM. The role of radiotherapy after radical prostatectomy. Urol Clin North Am. 2001;28:629-637.
93. Hawkins CA, Bergstralh EJ, Lieber MM, Zincke H. Influence of DNA ploidy and adjuvant treatment on progression and survival in patients with pathologic stage T3 (PT3) prostate cancer after radical retropubic prostatectomy. Urology. 1995;46:356-364.
94. Bolla M, Van Poppel H, Van Cangh P, et al. Does post-operative radiotherapy (P-RXT) after radical prostatectomy (Px) improve progression-free survival (PFS) in pT3N0 prostate cancer (PC)? (EORTC 22911) [abstract]. Prog Proc Am Soc Clin Oncol. 2004;23:4504.
95. Ferguson JK, Oesterling JE. Patient evaluation if prostate-specific antigen becomes elevated following radical prostatectomy or radiation therapy. Urol Clin North Am. 1994;21:677-685.
96. Koppie TM, Grossfeld GD, Nudell DM, Weinberg VK, Carroll PR. Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy? J Urol. 2001;166:111-115.
97. Fowler JE Jr, Brooks J, Pandey P, Seaver LE. Variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy. J Urol. 1995;153(3, pt 2):1011-1014.
98. Thomas CT, Bradshaw PT, Pollock BH, et al. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol. 2003;21:1715-1721.
99. Pisansky TM, Kozelsky TF, Myers RP, et al. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol. 2000;163:845-850.
100. Stephenson AJ, Shariat SF, Zelefsky MJ, et.al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004;291:1325-1332.
101. vander Kooy MJ, Pisansky TM, Cha SS, Blute ML. Irradiation for locally recurrent carcinoma of the prostate following radical prostatectomy. Urology. 1997;49:65-70.
102. Rogers R, Grossfeld GD, Roach M III, Shinohara K, Presti JC Jr, Carroll PR. Radiation therapy for the management of biopsy proved local recurrence after radical prostatectomy. J Urol. 1998;160:1748-1753.
103. Macdonald OK, Schild SE, Vora SA, et al. Salvage radiotherapy for palpable, locally recurrent prostate cancer after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2004;58:1530-1535.
104. Grossfeld GD, Olumi AF, Connolly JA, et al. Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity. J Urol. 1998;159:1437-1443.
105. Pilepich MV, Prasad SC, Perez CA. Computed tomography in definitive radiotherapy of prostatic carcinoma, part 2: definition of target volume. Int J Radiat Oncol Biol Phys. 1982;8:235-239.
106. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341:1781-1788.
107. Summers RM, Korobkin M, Quint LE, et al. Pelvic CT findings after radical prostatectomy. J Comput Assist Tomogr. 1993;17:767-771.
108. Teh BS, Mai WY, Augspurger ME, et al. Intensity modulated radiation therapy (IMRT) following prostatectomy: more favorable acute genitourinary toxicity profile compared to primary IMRT for prostate cancer [published correction appears in Int J Radiat Oncol Biol Phys. 2001;49:1529]. Int J Radiat Oncol Biol Phys. 2001;49:465-472.
109. Van Cangh PJ, Richard F, Lorge F, et al. Adjuvant radiation therapy does not cause urinary incontinence after radical prostatectomy: results of a prospective randomized study. J Urol. 1998;159:164-166.
110. Formenti SC, Lieskovsky G, Simoneau AR, et al. Impact of moderate dose of postoperative radiation on urinary continence and potency in patients with prostate cancer treated with nerve sparing prostatectomy. J Urol. 1996;155:616-619.
111. Bastasch MD, Teh BS, Mai WY, et al. Post-nerve-sparing prostatectomy, dose-escalated intensity-modulated radiotherapy: effect on erectile function. Int J Radiat Oncol Biol Phys. 2002;54:101-106.